These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8588767)

  • 21. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
    Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
    J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer].
    Shinagawa K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Mizunuma N
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3277-81. PubMed ID: 3143311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer.
    Scinto AF; Cercato MC; Botti C; Tonachella R; Ferraresi V; Del Bianco S; Sacchi I; Cognetti F
    Eur J Cancer; 1994; 30A(9):1285-8. PubMed ID: 7999414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
    Chan S; Davidson N; Juozaityte E; Erdkamp F; Pluzanska A; Azarnia N; Lee LW
    Ann Oncol; 2004 Oct; 15(10):1527-34. PubMed ID: 15367414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
    Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S
    J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
    de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
    Takashima S; Saeki T; Adachi I; Watanabe T; Sasaki Y; Murai H; Tabei T; Ogita M; Sano M; Kanda K; Shimoyama M
    Jpn J Clin Oncol; 1997 Oct; 27(5):325-30. PubMed ID: 9390210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
    Andersson H; Friberg LG; Horvath G; Johansson O; Akesson M; Westberg R
    Acta Oncol; 1995; 34(6):821-7. PubMed ID: 7576751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of second-line treatment with high-dose cyclophosphamide in recurrent metastatic breast cancer.
    Hansen F; Møller P; Skovsgaard T
    Cancer Chemother Pharmacol; 1996; 37(4):377-81. PubMed ID: 8548885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.
    Gregory RK; Johnston SR; Smith IE; Miles D
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):47-9. PubMed ID: 11098493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study.
    Giotta F; Lorusso V; Maiello E; Filippelli G; Valerio MR; Caruso M; Verderame F; Latorre A; Colucci G
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi66-9. PubMed ID: 17591836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
    Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
    Joensuu H; Holli K; Heikkinen M; Suonio E; Aro AR; Hietanen P; Huovinen R
    J Clin Oncol; 1998 Dec; 16(12):3720-30. PubMed ID: 9850014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.